Mr. Bazemore brings over 30 years of extensive leadership experience in the biopharmaceutical industry with a focus on growing rare disease companiesARLINGTON, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) - ...

KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative ...

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sepracor Inc. and Dainippon Sumitomo Pharma Co., Ltd. (DSP) today announce the resignation of Adrian Adams as President and Chief Executive Officer and Director of ...

Japanese pharmaceutical giant Dainippon Sumitomo Pharma Co. has completed its $2.6 billion acquisition of Sepracor Inc., triggering change-in-control provisions at the local drug maker that could ...

Submission includes data from three Phase III studies in over 1,000 patients from 23 countries Represents Sepracor's first NDS in Canada since strategic acquisition of Oryx Pharmaceuticals in June ...

Marlborough-based drug maker Sepracor Inc. has completed a $139 million tender offer for some of its outstanding convertible notes. Concluding at 12 a.m. this morning, the offer was for the company's ...

Marlborough-based Sepracor Inc. announced that it has settled a patent dispute over its Xopenex brand asthma inhaler with Teva Pharmaceuticals USA Inc. and Barr Laboratories. Under the agreement ...

Overall planned operating expense reduction of approximately $210.0 million, of which approximately $20.0 million of cost savings was realized in the fourth quarter of 2008 and approximately $190.0 ...

NEW YORK (Reuters) - Sepracor Inc said on Thursday late-stage studies of its experimental epilepsy treatment showed a significant reduction in partial seizures when the product was given along with ...

NEW YORK Marlborough, Mass.-based pharmaceutical company Sepracor has shelled out $50 million for a Canadian drug manufacturer, Sepracor announced Tuesday. Sepracor bought Canada’s Oryx ...

Agreements cover a company acquisition for $50 million and rights to enhance brand management within its respiratory disease portfolio. Sepracor reports multiple deals with the Arrow Group, including ...

Adam Greene - J.P. Morgan Securities Inc. Welcome to Sepracor's Fourth Quarter and Full Year 2007 Earnings Conference Call. Hosting the call today from Sepracor is; Mr. Adrian Adams, President and ...